For two years after gaining approval of its HIV product Fuzeon, Trimeris Inc. has worked to develop next-generation peptide fusion inhibitors, but now it will branch its HIV research into a whole new area - small molecules. (BioWorld Today)

After disappointing Phase III data for the lung cancer drug Xyotax, Cell Therapeutics Inc. has sold its one marketed product - Trisenox - to Cephalon Inc. for up to $170 million. (BioWorld Today)

Vertex Pharmaceuticals Inc. sold 11.75 million shares to raise gross proceeds of $152.8 million, the second highest amount of any biotech follow-on or initial public offering this year. (BioWorld Today)